comparemela.com

Latest Breaking News On - Mantle cell lymphoma - Page 12 : comparemela.com

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Andre goyJohn theurer cancer centerHackensack meridian health oncology care transformation servicesHackensack university medical centerLymphoma divisionAsh annual meeting and expositionOnclive tvMantle cell lymphomaMash 2023

Lisocabtagene Maraleucel in R/R MCL: Primary Analysis Results from the MCL Cohort of the Single-Arm, Multicenter, Seamless Design TRANSCEND NHL 001 Study

Alexey Danilov, MD, PhD, reviews data from the TRANSCEND NHL 001 study investigating lisocabtagene maraleucel in patients with relapsed/refractory mantle cell lymphoma.

Alexey danilovLisocabtagene maraleucelInternational conference on malignant lymphomaPrimary analysis resultsSeamless designPartnership withInternational conferenceMalignant lymphomaTranscend nhl 001Relapsed refractory mantle cell lymphomaLiso celRelapsed refractory mclMantle cell lymphomaTranscend nhl 001 studyRr mclTranscend nhl 001 results

Dr Goy on the Influence of High-Risk Features on Treatment Decision-Making in MCL

Andre Goy, MD, discusses the prevalence of high-risk clinical features in patients with mantle cell lymphoma and their influence on treatment approaches.

Andre goyInternational prognostic indexLymphoma divisionHackensack university medical centerJohn theurer cancer centerHackensack meridian health oncology care transformation servicesPrognostic indexGenetic abnormalitiesMantle cell lymphomaHigh risk features

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

SEATTLE, Dec. 05, 2023 Adaptive Biotechnologies Corporation , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to.

United statesSan diegoKarina calzadillaSusan bobulskyErica jonesIdecabtagene vicleucelElranatamab monotherapyLenalidomide viDaratumumab krdObinutuzumab clbCellectis biologicsLisocabtagene maraleucelA wisconsin oncology network studyAdaptive biotechnologies corporation nasdaqMeeting of the american society hematologyDrug administration

Rituximab Maintenance Boosts Survival for Older Adults With MRD-Negative MCL

Patients with treatment-sensitive disease may benefit most from continued treatment, says expert

United statesFox chase cancer centerDana farber cancer instituteChristiane pottChristine ryanHenryc fungChristian albrechts university in kielEuropean mantle cell lymphoma elderlyChristian albrechts universityAnn arborClin oncolMantle cell lymphoma

vimarsana © 2020. All Rights Reserved.